1. Epidemiology and Global Health
  2. Microbiology and Infectious Disease
Download icon

Origins of the 2009 H1N1 influenza pandemic in swine in Mexico

  1. Ignacio Mena
  2. Martha I Nelson
  3. Francisco Quezada-Monroy
  4. Jayeeta Dutta
  5. Refugio Cortes-Fernández
  6. J Horacio Lara-Puente
  7. Felipa Castro-Peralta
  8. Luis F Cunha
  9. Nídia Sequeira Trovão
  10. Bernardo Lozano-Dubernard
  11. Andrew Rambaut
  12. Harm van Bakel
  13. Adolfo García-Sastre  Is a corresponding author
  1. Icahn School of Medicine at Mount Sinai, United States
  2. National Institutes of Health, United States
  3. Laboratorio Avi-Mex, Mexico
Research Article
  • Cited 87
  • Views 10,343
  • Annotations
Cite this article as: eLife 2016;5:e16777 doi: 10.7554/eLife.16777

Abstract

Asia is considered an important source of influenza A virus (IAV) pandemics, owing to large, diverse viral reservoirs in poultry and swine. However, the zoonotic origins of the 2009 A/H1N1 influenza pandemic virus (pdmH1N1) remain unclear, due to conflicting evidence from swine and humans. There is strong evidence that the first human outbreak of pdmH1N1 occurred in Mexico in early 2009. However, no related swine viruses have been detected in Mexico or any part of the Americas, and to date the most closely related ancestor viruses were identified in Asian swine. Here, we use 58 new whole-genome sequences from IAVs collected in Mexican swine to establish that the swine virus responsible for the 2009 pandemic evolved in central Mexico. This finding highlights how the 2009 pandemic arose from a region not considered a pandemic risk, owing to an expansion of IAV diversity in swine resulting from long-distance live swine trade.

Article and author information

Author details

  1. Ignacio Mena

    Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Martha I Nelson

    Division of International Epidemiology and Population Studies,Fogarty International Center, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Francisco Quezada-Monroy

    Laboratorio Avi-Mex, Mexico City, Mexico
    Competing interests
    The authors declare that no competing interests exist.

  4. Jayeeta Dutta

    Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Refugio Cortes-Fernández

    Laboratorio Avi-Mex, Mexico City, Mexico
    Competing interests
    The authors declare that no competing interests exist.

  6. J Horacio Lara-Puente

    Laboratorio Avi-Mex, Mexico City, Mexico
    Competing interests
    The authors declare that no competing interests exist.

  7. Felipa Castro-Peralta

    Laboratorio Avi-Mex, Mexico City, Mexico
    Competing interests
    The authors declare that no competing interests exist.

  8. Luis F Cunha

    Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Nídia Sequeira Trovão

    Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Bernardo Lozano-Dubernard

    Laboratorio Avi-Mex, Mexico City, Mexico
    Competing interests
    The authors declare that no competing interests exist.

  11. Andrew Rambaut

    Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. Harm van Bakel

    Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  13. Adolfo García-Sastre

    Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, United States
    For correspondence
    adolfo.garcia-sastre@mssm.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Richard A Neher, Max Planck Institute for Developmental Biology, Germany

Publication history

  1. Received: April 8, 2016
  2. Accepted: June 13, 2016
  3. Accepted Manuscript published: June 28, 2016 (version 1)
  4. Version of Record published: July 22, 2016 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 10,343
    Page views
  • 1,160
    Downloads
  • 87
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Categories and tags

Research organism

Further reading

    1. Epidemiology and Global Health
    2. Evolutionary Biology

    COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest

    Albert Tian Chen et al.
    Research Article

    COVID-19 CG (covidcg.org) is an open resource for tracking SARS-CoV-2 single-nucleotide variations (SNVs), lineages, and clades using the virus genomes on the GISAID database while filtering by location, date, gene, and mutation of interest. COVID-19 CG provides significant time, labor, and cost-saving utility to projects on SARS-CoV-2 transmission, evolution, diagnostics, therapeutics, vaccines, and intervention tracking. Here, we describe case studies in which users can interrogate (1) SNVs in the SARS-CoV-2 spike receptor binding domain (RBD) across different geographical regions to inform the design and testing of therapeutics, (2) SNVs that may impact the sensitivity of commonly used diagnostic primers, and (3) the emergence of a dominant lineage harboring an S477N RBD mutation in Australia in 2020. To accelerate COVID-19 efforts, COVID-19 CG will be upgraded with new features for users to rapidly pinpoint mutations as the virus evolves throughout the pandemic and in response to therapeutic and public health interventions.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease

    Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events

    Ashish Goyal et al.
    Research Article

    SARS-CoV-2 is difficult to contain because many transmissions occur during pre-symptomatic infection. Unlike influenza, most SARS-CoV-2 infected people do not transmit while a small percentage infect large numbers of people. We designed mathematical models which link observed viral loads with epidemiologic features of each virus, including distribution of transmissions attributed to each infected person and duration between symptom onset in the transmitter and secondarily infected person. We identify that people infected with SARS-CoV-2 or influenza can be highly contagious for less than one day, congruent with peak viral load. SARS-CoV-2 super-spreader events occur when an infected person is shedding at a very high viral load and has a high number of exposed contacts. The higher predisposition of SARS-CoV-2 towards super-spreading events cannot be attributed to additional weeks of shedding relative to influenza. Rather, a person infected with SARS-CoV-2 exposes more people within equivalent physical contact networks, likely due to aerosolization.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease

    The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

    Zharko Daniloski et al.
    Research Article Updated

    A novel variant of the SARS-CoV-2 virus carrying a point mutation in the Spike protein (D614G) has recently emerged and rapidly surpassed others in prevalence. This mutation is in linkage disequilibrium with an ORF1b protein variant (P314L), making it difficult to discern the functional significance of the Spike D614G mutation from population genetics alone. Here, we perform site-directed mutagenesis on wild-type human-codon-optimized Spike to introduce the D614G variant. Using multiple human cell lines, including human lung epithelial cells, we found that the lentiviral particles pseudotyped with Spike D614G are more effective at transducing cells than ones pseudotyped with wild-type Spike. The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2. Furthermore, trans-complementation of SARS-CoV-2 virus with Spike D614G showed an increased infectivity in human cells. Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants, the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.